, Columnist
Prasad’s FDA Exit Offers Relief — Not Resolution
On his way out.
Source: U.S. Food and Drug Administration/AP Photo
The revolving door at the Food and Drug Administration has pushed out another top official: Vinay Prasad, the controversial head of the agency’s vaccine and gene therapy arm, will depart in April.
Patients and industry alike should breathe a little easier. The FDA has spent the last year embroiled in controversy and chaos — much of it due to Prasad’s top-down approach to regulation and dysfunctional leadership style.